What This Bill Does
This House resolution supports designating June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week." It does not create a new federal program, spending level, or benefit; instead, it expresses congressional support for awareness, education, research, and better access to care for people with hidradenitis suppurativa (HS). The resolution focuses on patients, caregivers, and health professionals, with the goal of improving recognition and treatment of a chronic skin disease that the text says affects about 3.3 million Americans.
- Supports June 1–7, 2026 as "Hidradenitis Suppurativa Awareness Week."
- Says HS affects approximately 3,300,000 people in the United States.
- Notes that 75 percent of people with HS are misdiagnosed or diagnosed after age 25.
- Recognizes only 3 FDA-approved biologic therapies for HS.
- Calls for better screening, culturally competent care, research, and access to treatment.
Who This Bill Affects
For the general public, this resolution has little direct day-to-day effect because it does not change eligibility, benefits, or federal funding. For people with hidradenitis suppurativa and their caregivers, it could still help by drawing attention to a disease that the text says is frequently misdiagnosed, under-treated, and associated with serious physical and psychological harm. It may also encourage clinicians, researchers, and policymakers to focus more on earlier diagnosis, better access to biologics, and broader care options.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- People living with hidradenitis suppurativa They may support the resolution because it publicly recognizes a painful, often misunderstood disease and highlights the need for earlier diagnosis and better treatment. Awareness can reduce stigma around symptoms like drainage, odor, and scarring, which the resolution says cause profound psychological distress.
- Dermatologists and other clinicians Health professionals may back the measure because it emphasizes education, screening, and culturally competent care. The resolution points to high misdiagnosis rates and delayed diagnosis, which clinicians may see as barriers to better outcomes and lower long-term costs.
- Medical researchers and patient advocates They may support it because it calls for biomedical research into HS pathogenesis, biomarkers, treatment efficacy, and long-term outcomes. A congressional resolution can help elevate HS on the research agenda and support efforts to expand treatment options beyond the three FDA-approved biologics mentioned in the text.
- Fiscal conservatives They may object to Congress spending time on a symbolic resolution rather than substantive legislation, especially because it does not itself fund research or expand coverage. Their concern would be that awareness designations can raise expectations without delivering concrete policy changes.
- Lawmakers skeptical of nonbinding resolutions Some members may argue that a resolution is too limited to address the real problems it describes, such as delayed diagnosis and access to care. They may prefer legislation that changes reimbursement, research funding, or federal health programs instead of a commemorative designation.
- Healthcare payers concerned about future mandates Insurers or employers could worry that heightened federal attention to HS may eventually lead to pressure for broader coverage of biologics, wound care, or specialty services. Even though this resolution does not mandate those changes, it explicitly endorses improving access to existing therapies and care.
Key Implications
-
“"supports the designation of 'Hidradenitis Suppurativa Awareness Week'"”
This is a symbolic congressional endorsement of a week-long awareness campaign. It does not itself create a legal requirement, but it can help drive public education and advocacy efforts.
-
“"75 percent of individuals with HS are misdiagnosed or not diagnosed until after age 25"”
The resolution identifies delayed diagnosis as a major problem. For patients, that can mean years of untreated symptoms, worsening disease, and more expensive or invasive care later.
-
“"there are currently only 3 biologic therapies approved by the Food and Drug Administration"”
The text highlights a limited treatment landscape. That implies many patients may have few effective options and supports the call for more research and additional therapies.
-
“"improving access to biologic therapies, wound care, and comprehensive care"”
This clause points to access barriers beyond diagnosis alone. It suggests that even when treatments exist, patients may still struggle to obtain specialty care, wound management, or ongoing comprehensive treatment.
-
“"promoting timely and accurate diagnosis... through improved screening and culturally competent care"”
The resolution links better outcomes to earlier recognition and care that is responsive to different patient backgrounds. In practice, that means training and awareness efforts aimed at reducing missed diagnoses and unequal treatment experiences.
Latest Status
June 2, 2026
Referred to the House Committee on Energy and Commerce.
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.